uniQure (NASDAQ:QURE) Stock Rating Upgraded by Barclays

uniQure (NASDAQ:QURE) was upgraded by equities research analysts at Barclays to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other equities research analysts have also recently issued reports on QURE. The Goldman Sachs Group decreased their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Leerink Partners dropped their target price on uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a report on Monday, November 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Wells Fargo & Company cut their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Finally, Stifel Nicolaus reduced their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.33.

uniQure Stock Performance

Shares of QURE stock opened at $23.02 on Tuesday. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The stock has a 50 day simple moving average of $23.81 and a 200-day simple moving average of $28.31. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -5.24 and a beta of 0.68.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $4.46 million. On average, equities analysts forecast that uniQure will post -3.75 EPS for the current year.

Insider Activity

In other uniQure news, Director Jack Kaye sold 6,390 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. This trade represents a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 102,247 shares of company stock valued at $2,839,298. 4.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of QURE. Private Trust Co. NA acquired a new position in uniQure during the third quarter valued at approximately $28,000. Jones Financial Companies Lllp raised its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 533 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares during the last quarter. Finally, FNY Investment Advisers LLC grew its position in uniQure by 76.7% during the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 718 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.